José
Palacios Calvo
Profesor/a Titular Universidad
![Foto de José](/img/nophoto.png)
![Foto de Hospital Vall d'Hebron](/img/noimage_org.png)
Hospital Vall d'Hebron
Barcelona, EspañaPublications in collaboration with researchers from Hospital Vall d'Hebron (21)
2024
-
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology
2022
-
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
Journal of Personalized Medicine, Vol. 12, Núm. 11
2021
-
Epithelial mesenchymal transition and immune response in metaplastic breast carcinoma
International Journal of Molecular Sciences, Vol. 22, Núm. 14
2020
-
Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences
American Journal of Surgical Pathology, Vol. 44, Núm. 5, pp. 649-656
-
Molecular features of metaplastic breast carcinoma: An infrequent subtype of triple negative breast carcinoma
Cancers, Vol. 12, Núm. 7, pp. 1-13
2018
-
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)
Clinical and Translational Oncology
-
Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia
-
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer
Journal of Pathology, Vol. 241, Núm. 4, pp. 475-487
2016
-
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer
Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308
2013
-
Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»
Revista Espanola de Patologia
-
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525
2012
-
Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease
Molecular and Cellular Endocrinology, Vol. 358, Núm. 2, pp. 244-255
-
Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon
Revista Espanola de Patologia
-
The EMT signaling pathways in endometrial carcinoma
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 715-720
2011
-
Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico
Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48
-
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651
2009
-
Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16
2006
-
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
Nature Genetics, Vol. 38, Núm. 5, pp. 566-569